Celldex Therapeutics (CLDX) Tax Provisions (2017 - 2021)

Celldex Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at -$227000.0 for Q3 2021.

• In Q3 2021, Tax Provisions changed N/A year-over-year to -$227000.0; the TTM figure through Dec 2021 stood at $673000.0 (up 113.62% YoY), while the FY2023 annual figure was -$29.7 million, down 25.91% from the prior year.
• Tax Provisions for Q3 2021 stood at -$227000.0, down from $900000.0 in the prior quarter.
• The five-year high for Tax Provisions was $900000.0 in Q4 2020, with the low at -$19.1 million in Q4 2017.
• The 4-year median for Tax Provisions is -$513500.0 (2018), against an average of -$3.8 million.
• Peak annual rise in Tax Provisions reached 70.44% in 2018, while the deepest fall reached 70.44% in 2018.
• Celldex Therapeutics' Tax Provisions stood at -$19.1 million in 2017, then jumped by 70.44% to -$5.6 million in 2018, then surged by 115.95% to $900000.0 in 2020, then slumped by 125.22% to -$227000.0 in 2021.
• Business Quant data shows CLDX's Tax Provisions at -$227000.0 in Q3 2021, $900000.0 in Q4 2020, and -$200000.0 in Q2 2020.